Biogen Inc (MIL:1BIIB)
€ 141.3 0 (0%) Market Cap: 20.87 Bil Enterprise Value: 25.62 Bil PE Ratio: 13.49 PB Ratio: 1.33 GF Score: 53/100

Biogen Inc at Stifel CNS Days (Virtual) Transcript

Mar 28, 2022 / 02:15PM GMT
Paul Andrew Matteis
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst

Great. Thank you very much, everybody. It's my pleasure to be hosting Priya Singhal, Biogen's Interim Head of Research and Development, this morning. We'll have a lot to talk about as it relates to Alzheimer's, neuropsychiatry, antisense oligonucleotides and anything else Priya thinks that I'm overlooking here that definitely needs more attention.

Questions & Answers

Paul Andrew Matteis;Priya Singhal
Stifel, Nicolaus & Company, Incorporated, Research Division - Co-Head of the Biotech Team, MD & Senior Analyst;Biogen Inc. - Senior VP, Head of Global Safety

But maybe we can start with conversation around Alzheimer's, Priya. And I assume there's not a ton you can say, but I'd be remiss at not at least asking for an update on where things stand ahead of the final NCD and if you think there's any sort of plausible path to materially modifying things as we get the final decision?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot